About Us

Mr. Tian currently serves as Chairman and Chief Executive Officer of JW Therapeutics. He has more than 20 years of experience in the biopharmaceutical industry, with extensive expertise in oncology commercialization, medical affairs, clinical research and development, operations management and strategic planning. Mr. Tian has long focused on innovative oncology therapies and has held multiple senior leadership positions at multinational pharmaceutical companies, leading domestic innovative pharmaceutical companies and biotechnology companies. He brings comprehensive leadership experience across product strategy, research and development, market access, commercial execution and overall corporate management.

• Mr. Tian currently serves as Chairman and Chief Executive Officer of JW Therapeutics. He has more than 20 years of experience in the biopharmaceutical industry, with extensive expertise in oncology commercialization, medical affairs, clinical research and development, operations management and strategic planning. Mr. Tian has long focused on innovative oncology therapies and has held multiple senior leadership positions at multinational pharmaceutical companies, leading domestic innovative pharmaceutical companies and biotechnology companies. He brings comprehensive leadership experience across product strategy, research and development, market access, commercial execution and overall corporate management.
• From 2019 to 2021, Mr. Tian served as Deputy General Manager of the Oncology Business Unit at Hengrui Pharmaceuticals, where he was responsible for marketing and medical affairs. He led the launch and commercialization of the PD-1 product and advanced the launch preparation and commercialization of multiple innovative oncology medicines. Earlier in his career, Mr. Tian served as Marketing Director at Roche Pharmaceuticals, where he was responsible for several key oncology products. He also served as Senior International Product Manager at Pfizer, supporting business expansion across multiple emerging markets.
• Mr. Tian graduated from Shanghai Jiao Tong University School of Medicine with a master’s degree in hematology.

Shawn He, PhD, serves as Chief Scientific Officer at JW Therapeutics. Prior to joining JW, he was Chief Scientific Officer at Cure Genetics, where he established a CAR-NKT pipeline targeting solid tumors. Previously, he served as Executive Vice President and Head of R&D at Celularity, leading the development of novel allogeneic CAR-T and CAR-NK therapies.

• Earlier in his career at Celgene, Dr. He held roles of increasing responsibility and advanced three cell therapy programs through IND-enabling studies, all of which subsequently entered clinical development across eight indications.
• Dr. He received his PhD from the University of Maryland, College Park.

Mr. EJ Jiang serves as Vice President of Commercial and Chief of Staff at JW Therapeutics. He is responsible for the Company’s commercialization strategy, operational
management and cross-functional coordination. 

• Mr. Jiang has accumulated nearly 20 years of experience in the biopharmaceutical industry with extensive expertise in commercialization, strategic planning, market access and business development.Prior to joining our Group, Mr. Jiang served as deputy general manager of the oncology business unit at GenSci Pharmaceutical, where he was responsible for strategy, marketing, sales force effectiveness and business development. 
• Mr. Jiang obtained a master’s degree in industrial engineering from the University of Wisconsin–
  Madison and a bachelor’s degree in theoretical and applied mechanics, with a second major in economics, from Fudan University in the PRC.

Zhidan Daniel Tu serves as Head of Business Development, Alliance Management and Strategy at JW Therapeutics, where he leads business development, external collaborations, alliance management and corporate strategy initiatives. In this role, he focuses on external growth strategy, partnership development and alliance execution to support JW Therapeutics’ long-term development.

• Dr. Tu brings extensive experience across biotech business development, corporate development, alliance management and operations. Prior to joining JW Therapeutics, he served as Head of BD and Operations at Zipcode Bio, Head of Business Development and Operations at RVAC Medicines, and Director of Business Development at Legend Biotech. Earlier in his career, he held multiple scientific and commercial leadership roles at GenScript Corporation, including Commercial Head of the Discovery Biology Business Unit and Technical Lead of the Antibody Department. Over the years, he has worked across multiple therapeutic modalities and technology platforms, including antibodies, cell therapies, nucleic acid-based therapeutics and delivery systems.
• Dr. Tu received his Ph.D. in Immunology through a joint training program at Case Western Reserve University and West China Hospital of Sichuan University, and his B.S. in Biotechnology from Sichuan University.

Mr. Sheng Wang currently serves as Head of the Suzhou Plant at JW Therapeutics. He is responsible for the commercial production of Carteyva®, the first Class I CD19-targeted CAR-T therapy approved in China, as well as the manufacturing of clinical-stage products, including FAST CAR-T and solid tumor programs. He also oversees the clinical and commercial production of suspension lentivirus (sLVV).

• Previously, Mr. Wang led his team to successfully pass multiple regulatory inspections, including pre-approval inspections and post-approval variations such as capacity expansion, addition of new production lines, and establishment of positive-pressure cleanrooms.
• With 18 years of experience in the pharmaceutical industry, Mr. Wang has extensive expertise in manufacturing operations, lean management, aseptic assurance, supply chain, and project management. Prior to joining JW Therapeutics, Mr. Wang served as General Manager of the Nanjing Manufacturing Site at IASO Biotherapeutics, where he was responsible for the production of Fucaso®. He also led cross-border “cell therapy export” initiatives, resulting in the first Chinese cell therapy product to pass an official PIC/S inspection.
• Earlier in his career, Mr. Wang worked at Novartis, where he was involved in manufacturing management, supply chain planning, and quality culture initiatives, gaining strong hands-on experience in production and quality management.